Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion

AIM：To compare changes in visual acuity and macular edema in patients with central retinal vein occlusion（CRVO）treated with intravitreal injections of bevacizumab,macular grid photocoagulation combined with pan retinal photocoagulation（PRP）,or both（bevacizumab＋grid＋PRP）.· METHODS：Our study is a retrospective cohort clinical study that examined patients that suffered from ischemic CRVO with macular edema.Study inclusion criteria were ischemic CRVO with macula edema and the availability of complete medical records for at least 12 mo after treatment.Excluded were patients with diabetes or any other retinal disease.We reviewed the medical records of patients treated in one ophthalmology departmentcomparing changes in visual acuity and macular edema in patients treated with intravitreal injections of bevacizumab vs those that were treated with macular grid photocoagulation and PRP or both.The main outcome measures were the differences in best corrected visual acuity（BCVA） and in macular thickness,as assessed by optical coherence tomography,between the enrollment and the final follow up visits.· RESULTS：Sixty-five patients met inclusion criteria.There were no statistically significant differences among the three groups in the mean changes in macular thickness as measured by ocular coherence tomography（131.5±41.2,108.6±29.2,and 121.1±121.1,P=0.110）,or in visual acuity（0.128±0.077,0.088±0.057,and 0.095±0.065）,for intravitreal injections,macular grid photocoagulation＋PRP and a combination of the treatments,respectively,P =0.111.The proportions of patients with macular edema after treatment were：26.1%,28.6%,and 14.3%,respectively,P=0.499.· CONCLUSION：Similar benefit was observed for intravitreal injections,laser photocoagulation,or a combined regimen in the treatment of CRVO.A nonstatistically significant trend for reduction in macular edema was observed following combined treatment.

全氟化碳液体短期术后填塞治疗巨大视网膜裂孔(英文)

目的:探讨全氟化碳液体短期术后填塞治疗视网膜脱离伴巨大视网膜裂孔的有效性和安全性。方法:检索从1998-01/2010-12在单一的医疗中心治疗患者的病历数据。比较应用和没有应用全氟化碳液体的患者的视网膜复位成功率,视力预后及术后并发症。结果:术后,治疗组22眼(21例),对照组14眼(14例)视网膜均附着。两组的最终附着率分别为81.8%和42.9%(P<0.05)。治疗组4眼(18.2%),对照组7眼(50%)发展为重症增生性玻璃体视网膜病变和持续性视网膜脱离。治疗组73.3%,对照组26.7%患者的视力为6/12或更高(P<0.05)。治疗组50.0%,对照组14.3%患者视力提升;治疗组22.7%,对照组57.1%患者视力下降(P=0.054)。结论:视网膜脱离伴巨大视网膜裂孔使用全氟化碳液体作为短期术后填塞是安全的。全氟化碳液体在预防增生性玻璃体视网膜病变方面有效。

Prevalence of glaucoma in the Israeli Arab population

We describe the prevalence and treatment of glaucoma in a Muslim Arab population in Israel. Based on the medical records of 15 122 persons, the overall prevalence of glaucoma was 3.9%. Prevalence rates of primary open angle glaucoma（POAG） and primary angle-closure glaucoma（PACG） were 3.0% and 0.42%, respectively. Prevalence rates of women were 135% that of men considering all types of glaucoma, 143% for POAG, and 96% for PACG. Prostaglandin analogs and beta blockers, alone or combined with carbonic anhydrase inhibitors, were the preferred medications. Of 68 patients who underwent trabeculectomy, 27（39.7%） required medications, postoperatively, for treatment of glaucoma; following Ex-Press shunt surgery, 3/11（27.3%） required medications. During the last three years, 16（1.3%） individuals with POAG were recorded as legally blind as a result of glaucoma.

使用OCT评估多发性硬化症分期及其严重性（英文）

目的:评估光学相干层析成像(OCT)、多发性硬化病程(MS)和扩展伤残状态等级(EDSS)之间的联系。方法:前瞻性双盲研究。29例多发性硬化症确诊患者与29例正常人进行比较,年龄和性别匹配。所有受试者于同一天进行光学相干层析成像检查和神经扩展伤残状态等级测试。结果:多发性硬化症患者平均扩展伤残状态等级指数为3. 2,健康对照组为0. 03,多发性硬化症患者病程为11. 7a。多发性硬化症患者视网膜神经纤维层(RNFL)厚度显著较薄(P<0. 01)。多发性硬化病程与视网膜神经纤维层变薄之间存在相关性。扩展伤残状态等级与视网膜神经纤维层变薄之间呈相关趋势但无统计学意义。结论:较正常对照组,多发性硬化症患者RNFL较薄。多发性硬化症病程对RNFL厚度有直接影响。RNFL厚度与扩展伤残状态等级之间可能存在相关性。建议使用OCT作为多发性硬化症患者的检测和评估工具。